araag2/HINT huggingface dataset:
Clinical trial NCT00270894 (phase 2, status: completed)
Conditions: breast neoplasm
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: epirubicin, cyclophosphamide, docetaxel, trastuzumab
SMILES: CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=CC=NC(NC2=CC=C(C)C(=C2)S(N)(=O)=O)=N1, ClCCN(CCCl)P1(=O)NCCCO1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Non-pregnant females =/> 18 years of age

          -  Non-inflammatory breast cancer stage IIA - IIIC or high risk node negative

          -  Core biopsy of breast demonstrating invasive cancer and documented ER/PgR receptor
             status

          -  Normal cardiac function and adequate hematologic function

          -  Human epidermal growth factor receptor 2 protein (HER2) positive

          -  No evidence of metastatic disease

          -  ECOG Performance Status 0 - 1

          -  Women of childbearing potential must agree to using effective contraception while on
             treatment and for at least 3 months post-treatment

        Exclusion Criteria:

          -  Treated with other investigational drugs within 30 days

          -  Uncontrolled intercurrent disease or active infection

          -  Known sensitivity to e. coli-derived proteins or polysorbate 80

          -  Psychiatric illness or social situation that would limit study compliance

          -  Pre-existing peripheral neuropathy > Grade 1

          -  Cancer within 5 years of screening with the exception of surgically cured
             nonmelanomatous skin cancer; in-situ carcinoma of the cervix; or in-situ carcinoma of
             the breast

          -  Bilateral synchronous breast cancer

          -  Inflammatory breast cancer

          -  Women who are pregnant or breast feeding
Clinical trial NCT02088411 (phase 2, status: completed)
Conditions: wobenzym, osteoarthritis
ICD codes: M15.4, M15.0, M16.9, M17.9, M19.011, M19.012, M19.019
Drugs: diclofenac
SMILES: OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          -  Knee osteoarthritis confirmed by radiography or tomography

          -  Lequesne Functional Index score of 10-14

          -  WOMAC-A pain subscale score greater than or equal to 25

        Exclusion Criteria:

          -  History of knee trauma

          -  History of joint infection

          -  History of joint surgery

          -  History of intra-articular injection (viscotherapy)

          -  History of gastrointestinal diseases

          -  Use of corticosteroids

          -  Use of COX-II inhibitors

          -  Use of glucosamine/chondroitin

          -  Known sensitivity to paracetamol

          -  Known sensitivity to non-steroidal anti-inflammatory drugs (NSAIDs)

          -  Known sensitivity to oral enzymes
Clinical trial NCT00231608 (phase 2, status: completed)
Conditions: obesity
ICD codes: E66.8, E66.9, E66.1, O99.214, O99.215, O99.210, O99.211
Drugs: topiramate
SMILES: [H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2
Eligibility criteria:

        Inclusion Criteria:

          -  BMI >= 27 and =< 40

          -  a waist circumference >= 100 cm (39.4 inches)

          -  Baseline weight must be stable (varying no more than 4 kg (8.8 lbs)) for at least two
             months prior to enrollment

          -  Must be sedentary (less than one session of continuous moderate physical activity of
             30 min/week)

          -  Must have blood lipid disorder

          -  Must be non-smokers

        Exclusion Criteria:

          -  Patients with endocrine disease or other physical causes of obesity

          -  Patients with significantly abnormal hepatic liver function tests or renal disease

          -  History of schizophrenia, psychotic, or major affective disorder

          -  History of epilepsy

          -  History of eating disorders

          -  History of any other significant medical conditions
Clinical trial NCT01554176 (phase 2, status: terminated)
Conditions: major depressive disorder, recurrent
ICD codes: F33.0, F33.1, F33.9, F33.40, F33.41, F33.42, F33.2
Drugs: filorexant, placebo
SMILES: C[C@@H]1CC[C@@H](COC2=CC=C(F)C=N2)CN1C(=O)C1=CC(C)=CC=C1C1=NC=CC=N1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    low enrollment
  
Eligibility criteria:

        Inclusion Criteria:

          -  Participant is (a) male or (b) female and not of reproductive potential, or (c) female
             of reproductive potential has a serum beta-hCG level consistent with the nongravid
             state at screening and agrees to use acceptable contraception;

          -  Current primary diagnosis of recurrent major depressive disorder, without psychotic
             features, with a current moderate or severe depressive episode;

          -  Duration of the current major depressive episode must be at least 2 months but no more
             than 18 months at Screening;

          -  Participant has undergone an adequate trial of an antidepressant (one of identified
             SSRIs or SNRIs, or bupropion) for the current depressive episode.

        Key Exclusion Criteria:

          -  Current primary psychiatric diagnosis other than major depression;

          -  Lifetime diagnosis of bipolar disorder, schizophrenia, schizoaffective disorder, or
             other psychotic disorder;

          -  Alcohol or other substance abuse or dependence (excluding nicotine);

          -  Clinically significant abnormality or disease of the central nervous system (including
             dementia and other cognitive disorders or traumatic brain injury);

          -  Imminent risk of self-harm or of harm to others;

          -  Participant is a psychiatric inpatient;

          -  Participant has been on continuous antidepressant treatment for >18 months prior to
             Screening visit;

          -  Inadequate response to more than 3 adequate antidepressant trials (including the
             current antidepressant treatment trial) for treatment of the current depressive
             episode;

          -  Participant ever received electroconvulsive therapy, transcranial magnetic
             stimulation, or vagal nerve stimulation for treatment of depression;

          -  History of narcolepsy, cataplexy, circadian rhythm disorder, parasomnia, sleep-related
             breathing disorder, restless legs syndrome, periodic limb movement disorder, excessive
             daytime sleepiness or difficulty sleeping due to a medical condition;

          -  Clinical, laboratory, or electrocardiogram (ECG) evidence of significant systemic
             disease;

          -  Cardiovascular event (e.g., myocardial infarction) or procedure (e.g., coronary artery
             bypass surgery) within 3 months of study;

          -  History of malignancy ≤5 years prior to study, except for adequately treated basal
             cell or squamous cell skin cancer or in situ cervical cancer;

          -  Body Mass Index >40 kg/m^2;

          -  Pregnancy, breast-feeding, or expecting to become pregnant.
Clinical trial NCT00384930 (phase 2/phase 3, status: completed)
Conditions: benign prostatic hyperplasia
ICD codes: N40.0, N40.1
Drugs: tadalafil, tadalafil, tadalafil, tadalafil, placebo
SMILES: [H][C@]12CC3=C(NC4=CC=CC=C34)[C@H](N1C(=O)CN(C)C2=O)C1=CC2=C(OCO2)C=C1, [H][C@]12CC3=C(NC4=CC=CC=C34)[C@H](N1C(=O)CN(C)C2=O)C1=CC2=C(OCO2)C=C1, [H][C@]12CC3=C(NC4=CC=CC=C34)[C@H](N1C(=O)CN(C)C2=O)C1=CC2=C(OCO2)C=C1, [H][C@]12CC3=C(NC4=CC=CC=C34)[C@H](N1C(=O)CN(C)C2=O)C1=CC2=C(OCO2)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Males, 45 years or older, with benign prostatic hyperplasia, including lower urinary
             tract symptoms for at least 6 months prior to Visit 1 and an International Prostate
             Symptom Score (IPSS) greater than or equal to 13 at Visit 2.

          -  Agree not to use approved or experimental benign prostatic hyperplasia or erectile
             dysfunction treatments anytime during the study

          -  Have not taken finasteride or dutasteride therapy, any other lower urinary tract
             symptom (LUTS) therapy or phosphodiesterase type 5 (PDE5) inhibitors for specified
             duration of time prior to Visit 2.

          -  Have a prostate specific antigen (PSA) score within acceptable range defined for study
             or negative biopsy of the prostate for cancer within 12 months of Visit 1.

        Exclusion Criteria:

          -  History of urinary retention or lower urinary tract (bladder) stones 6 months before
             the start of the study

          -  History of bladder outlet obstruction or urethral obstruction due to stricture,
             valves, sclerosis, or tumor.

          -  History of cardiac conditions including angina requiring certain treatment with
             nitrates, heart disease or coronary conditions including myocardial infarction, bypass
             surgery, angioplasty or stent placement for a specified time before starting the
             study.

          -  Certain neurological conditions associated with bladder problems or injuries to the
             brain or spinal cord within a specified time before starting the study.

          -  Nitrate use
Clinical trial NCT00174369 (phase 2, status: terminated)
Conditions: carcinoma, non-small-cell lung
ICD codes: D02.20, D02.21, D02.22
Drugs: pd-0325901
SMILES: [H][C@@](O)(CO)CONC(=O)C1=C(NC2=CC=C(I)C=C2F)C(F)=C(F)C=C1
Reason stopped: 
    terminated [see detailed description for termination reason.]
  
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically documented non-small cell lung cancer with metastases (Stage IV or
             recurrent disease) or locally advanced (Stage IIIB) with malignant pleural effusion
             with no expectation of further effects of prior anticancer therapy, and resolution of
             all acute toxic effects

          -  Adequate renal, liver, and bone marrow function, determined within 2 weeks prior to
             the first treatment and an ECOG status of <=1.

          -  Must have evidence of progression of disease within 6 months of most recent prior
             systemic anticancer therapy.

        Exclusion Criteria:

          -  No parathyroid disorder or history of malignancy associated hypercalcemia

          -  No ongoing radiation therapy or radio-cytotoxic therapy within prior 4 weeks; No
             immunotherapy, biologic therapy, hormonal, or molecular targeted therapy within prior
             2 weeks

          -  No concurrent serious infection or life-threatening illness (unrelated to tumor)

          -  No history of a malignancy (other tha non-small cell lung cancer) except those treated
             with curative intent for skin cancer (other than melanoma) or in situ breast or
             cervical cancer or those treated with curative intent for any other cancer with no
             evidence of disease for 5 years.

          -  No active seizure disorders or untreated brain metastases.
Clinical trial NCT01235351 (phase 2, status: completed)
Conditions: myocardial infarction, percutaneous coronary intervention
ICD codes: I25.2, I21.9, I21.A1, I21.A9, I21.4, I22.2, I23.8, Y35.312S, Y35.313S, Y35.412S, Y35.413S, Y35.812S, Y35.813S, Y35.92XS
Drugs: clopidogrel, clopidogrel
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O, N[C@@H](CCCNC(N)=N)C(O)=O
Eligibility criteria:

        Inclusion Criteria (major):

          1. Between 18 and 75 years of age, inclusive.

          2. Have an indication for the use of clopidogrel defined as either spontaneous MI
             [hospitalized with final diagnosis of MI, excluding periprocedural or definite
             secondary MI (e.g., due to anemia or hypertensive emergency)] or PCI within the past 6
             months.

          3. Clinically stable and at least 4 weeks following the MI or PCI.

        Exclusion Criteria (major):

          1. Conditions that alter platelet function.

          2. Conditions that increase bleeding risk.
Clinical trial NCT00420082 (phase 2, status: completed)
Conditions: seasonal allergic rhinitis
ICD codes: J30.2
Drugs: bilastine, fexofenadine, cetirizine, placebo
SMILES: CCOCCN1C(=NC2=CC=CC=C12)C1CCN(CCC2=CC=C(C=C2)C(C)(C)C(O)=O)CC1, CC(C)(C(O)=O)C1=CC=C(C=C1)C(O)CCCN1CCC(CC1)C(O)(C1=CC=CC=C1)C1=CC=CC=C1, OC(=O)COCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Have a history of seasonal allergic rhinitis

          -  Have a positive (as defined in the protocol) skin prick or RAST test within 12 months
             prior to the screening visit

        Exclusion Criteria:

          -  Have a clinically significant illness or disease

          -  Have unstable asthma

          -  Has participated in a clinical trial 30 days prior to the screening visit
Clinical trial NCT00704678 (phase 2, status: completed)
Conditions: chronic kidney disease
ICD codes: I12.9, N18.9, I12.0, D63.1, N18.1, N18.5, I13.0
Drugs: sbr759, sevelamer hcl, sevelamer hcl, sevelamer hcl
SMILES: NCC=C.ClCC1CO1, NCC=C.ClCC1CO1, NCC=C.ClCC1CO1
Eligibility criteria:

        Inclusion criteria

          -  Men or women of at least 18 years old or 20 years old in Japan.

          -  Stable maintenance of hemodialysis 3 times per week.

          -  Controlled serum phosphate if under phosphate-binder therapy.

          -  Serum phosphate level > 6.0 mg/dL (> 1.9 mmol/L) prior to study treatment initiation.

        Exclusion criteria

          -  Peritoneal dialysis or a non-conventional hemodialysis technique .

          -  Parathyroidectomy or transplant scheduled during the study.

          -  Uncontrolled hyperparathyroidism

          -  History of hemochromatosis or ferritin > 800 µg/L.

          -  Clinically significant GI disorder

          -  Unstable medical condition other than Chronic Kidney Disease.

          -  Treated with sevelamer HCl monotherapy or SBR759.

          -  Treated with oral iron.

          -  Other protocol-defined inclusion/exclusion criteria may apply.
Clinical trial NCT01289821 (phase 2, status: completed)
Conditions: colorectal neoplasms
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: regorafenib (stivarga, bay73-4506), oxaliplatin, folinic acid, 5-fu (mfolfox6)
SMILES: O=[Zn], [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, NC1=NC(=O)C2=C(NC[C@H](CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N2C=O)N1, FC1=CNC(=O)NC1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female subjects aged ≥ 18 years

          -  Histological or cytological documentation of adenocarcinoma of the colon or rectum

          -  Suitable to receive mFOLFOX6 regimen as first line metastatic treatment

          -  At least 1 measurable lesion as per RECIST version 1.1

          -  Unresectable or unlikely becoming resectable metastatic disease

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1

          -  Life expectancy of at least 3 months

          -  Adequate bone marrow, liver, and renal function

        Exclusion Criteria:

          -  Prior systemic anticancer therapy for metastatic colorectal cancer (CRC). Adjuvant
             chemotherapy for CRC (Stage I, II, III) is permitted, if the adjuvant therapy ended >
             6 months before screening and recurrent disease was documented.

          -  Prior treatment with antivascular endothelial growth factor (anti-VEGF) agents and any
             signal transduction inhibitors (STIs)

          -  Uncontrolled hypertension

          -  Subjects with symptoms, signs, or history of brain metastases

          -  Any hemorrhage or bleeding event ≥ Common Terminology Criteria for Adverse Events
             (CTCAE) Grade 3 within 4 weeks of start of study treatment

          -  Sensory neuropathy (> CTCAE Grade 1), unresolved toxicity > CTCAE Grade 1 attributed
             to any prior therapy/procedure excluding alopecia
Clinical trial NCT01246583 (phase 2, status: completed)
Conditions: psoriasis
ICD codes: L40.0, L40.4, L40.8, L40.9, L40.1, L40.50
Drugs: cp-690,550 ointment 1, vehicle 1, cp-690,550 ointment 2, vehicle 2
SMILES: [H][C@@]1(C)CCN(C[C@]1([H])N(C)C1=NC=NC2=C1C=CN2)C(=O)CC#N, CC1=CC(O)=CC(C)=C1Cl, [H][C@@]1(C)CCN(C[C@]1([H])N(C)C1=NC=NC2=C1C=CN2)C(=O)CC#N, CC1=CC(O)=CC(C)=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          -  Mild to moderate chronic plaque psoriasis (psoriasis vulgaris), with the duration of
             at least 6 months;

          -  A target plaque of at least 9 sq. cm.

        Exclusion Criteria:

          -  Demonstrates "rebound" or "flare" of chronic plaque psoriasis;

          -  Non plaque form of psoriasis;

          -  Currently have or history of psoriatic arthritis;

          -  Current drug induced psoriasis;

          -  Currently on systemic therapy or was on systemic therapy for psoriasis within the
             previous 6 months;

          -  Currently on phototherapy for psoriasis or was on phototherapy within the previous 3
             months
Clinical trial NCT01496326 (phase 2, status: completed)
Conditions: osteoarthritis
ICD codes: M15.4, M15.0, M16.9, M17.9, M19.011, M19.012, M19.019
Drugs: ibuprofen, placebo
SMILES: CC1=CC(O)=CC(C)=C1Cl, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Main Inclusion Criteria:

          -  Male or female patients aged at least 40 years.

          -  Primary osteoarthritis in a single knee joint, grade II/III based on the Kellgren and
             Lawrence classification system.

          -  Radiographic evidence consistent with osteoarthritis carried out within 6 months
             before screening.

          -  pain is currently not adequately controlled with a simple analgesic or an NSAID OR
             would necessitate treatment, but is not yet treated.

        Main Exclusion Criteria:

          -  Concomitant presence of another type of continuous pain that is more severe in
             intensity in comparison with the osteoarthritis target joint pain

          -  Osteoarthritis causing significant pain in any joint other than the identified knee,
             or contralateral knee (≥ 20 mm pain) as confirmed by a separate VAS at visit 1 for any
             other painful joint concerned.

          -  Female patients who are pregnant or breast-feeding.
Clinical trial NCT01081678 (phase 2, status: completed)
Conditions: fracture healing
ICD codes: M84.350D, M84.350G, M84.454D, M84.454G, S02.411D, S02.411G, S02.412D
Drugs: placebo, romosozumab
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Males and females, age 55 to 95 years

          -  fresh unilateral low energy intertrochanteric or femoral neck fracture as the primary
             injury, confirmed by X-ray and in the opinion of the treating surgeon amenable to
             repair by internal fixation

          -  internal fixation of the fracture with devices approved by local regulatory agency,
             performed no later than 7 days after injury for intertrochanteric or undisplaced
             femoral neck fractures and no later than 2 days after injury for displaced femoral
             neck fractures

               -  intertrochanteric fracture: sliding hip screw or IM nail

               -  femoral neck fracture: sliding hip screw or at least 3 cancellous screws

        Exclusion Criteria:

          -  severe symptomatic osteoarthritis of the lower extremity

          -  inability to independently rise from armchair or walk 200 meters before hip fracture

          -  presence of concomitant injuries such as rib fractures, wrist fractures, or acute
             symptomatic vertebral fractures which severely impair the ability to rise from a chair

          -  associated extremity injuries including ipsilateral or contralateral fractures of the
             foot, tibia or fibula, wrist, humerus, femoral shaft, femoral head or hip dislocation,
             that may delay weight-bearing beyond one week after surgery

          -  head-injury, as defined by Glasgow Coma Scale < 13 prior to randomization

          -  use of bone grafts or bone substitutes at the time of fracture fixation

          -  major polytrauma or significant axial trauma, with Injury Severity Score > 16

          -  pathological fracture or history of metabolic or bone disease (except osteoporosis)
             that may interfere with the interpretation of the results, such as Paget's disease,
             rheumatoid arthritis, osteomalacia, osteopetrosis, ankylosing spondylitis, Cushing's
             disease, hyperprolactinemia

          -  history of symptomatic spinal stenosis that has not been surgically corrected. If
             surgically corrected, the subject must be asymptomatic to be eligible for the study.

          -  history of facial nerve paralysis

          -  malignancy (except fully resected cutaneous basal cell or squamous cell carcinoma,
             cervical carcinoma in situ) within the last 5 years

          -  history of solid organ or bone marrow transplants

          -  evidence of elevated transaminases (≥ 2.0 x upper limits of normal) or significantly
             impaired renal function (creatinine clearance of ≤ 30 mL/min)

          -  evidence of current hypercalcemia or hypocalcemia (outside of 1.1 x the normal range)

          -  bone morphogenic proteins (BMP)-2 or BMP-7 at the time of definitive fracture fixation
Clinical trial NCT00609622 (phase 2, status: terminated)
Conditions: colorectal neoplasms
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: sunitinib, mfolfox6, bevacizumab, mfolfox6
SMILES: CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Reason stopped: 
    see termination reason in detailed description.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Adenocarcinoma of the colon or rectum with locally advanced or metastatic disease

          -  Evidence of measurable disease per Response Evaluation Criteria in Solid Tumors
             (RECIST)

          -  Eastern Cooperative Oncology Group (ECOG) 0 or 1

        Exclusion Criteria:

          -  Previous treatment with Sutent, Avastin, or any other systemic therapy for locally
             advanced or metastatic colorectal cancer

          -  Less than 6 months since completion of adjuvant chemotherapy to documentation of
             recurrent disease

          -  History of cardiac disease

          -  Brain mets